A modified integrated genetic model for risk prediction in younger patients with acute myeloid leukemia

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Sloan, Caroline E ^a,b   Luskin, Marlise R ^b   Boccuti, Anne M ^b   Sehgal, Alison R ^c   Zhao, Jianhua ^b   Daber, Robert D ^b   Morrissette, Jennifer J D ^b   Luger, Selina M ^b   Bagg, Adam ^b   Gimotty, Phyllis A ^b   Carroll, Martin ^b,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; NUCLEOPHOSMIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; ASXL1 GENE; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DNMT3A GENE; FEMALE; FLT3 GENE; GENE; GENE MUTATION; GENETIC MODEL; GENETIC RISK; HUMAN; IDH1 GENE; IDH2 GENE; MALE; NPM1 GENE; OVERALL SURVIVAL; PHF6 GENE; PREDICTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; TET2 GENE; TRISOMY; ACUTE MYELOID LEUKEMIA; ADOLESCENT; BIOLOGICAL MODEL; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PROGNOSIS; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MODELS, GENETIC; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84962878143     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153016     Document Type: Article

References (29)

1. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075-4083. PMID: 11110676
2. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354-365. doi: 10.1182/blood-2009-11-254441 PMID: 20385793
3. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358:1909-1918. doi: 10.1056/NEJMoa074306 PMID: 18450602
4. Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE. Prognostic Significance of CEBPA Mutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of Double CEBPA Mutations and the Interaction With FLT3 and NPM1 Mutations. J Clin Oncol. 2010;28:2739-2747. doi: 10.1200/JCO.2009.26.2501 PMID: 20439648
5. Taskesen E, Bullinger L, Corbacioglu A, Sanders MA, Erpelinck C A J, Wouters BJ, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood. 2011;117:2469-2475. doi: 10.1182/blood-2010-09-307280 PMID: 21177436
6. Frohling S. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100:4372-4380. doi: 10.1182/blood-2002-05-1440 PMID: 12393388
7. Swerdlow Steven H, Campo Elias, Harris Nancy Lee, Jaffe Elaine S, Pileri Stefano A, Stein Harald, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008.
8. Mrozek K, Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman SP, et al. Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia. J Clin Oncol. 2012;30:4515-4523. doi: 10.1200/JCO.2012. 43.4738 PMID: 22987078
9. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453-474. doi: 10.1182/blood-2009-07-235358 PMID: 19880497
10. Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H, et al. TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol. 2011;29:1373-1381. doi: 10.1200/JCO.2010.32.7742 PMID: 21343549
11. Chou W-C, Chou S-C, Liu C-Y, Chen C-Y, Hou H-A, Kuo Y-Y, et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood. 2011;118:3803-3810. doi: 10.1182/blood-2011-02-339747 PMID: 21828143
12. Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrozek K, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood. 2011;118:6920-6929. doi: 10.1182/blood-2011-08-368225 PMID: 22031865
13. Van Vlierberghe P, Patel J, Abdel-Wahab O, Lobry C, Hedvat CV, Balbin M, et al. PHF6 mutations in adult acute myeloid leukemia. Leukemia. 2011;25:130-134. doi: 10.1038/leu.2010.247 PMID: 21030981
14. Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia. N Engl J Med. 2012;366:1079-1089. doi: 10. 1056/NEJMoa1112304 PMID: 22417203
15. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363:2424-2433. doi: 10.1056/NEJMoa1005143 PMID: 21067377
16. Abdel-Wahab. Molecular genetics of acute myeloid leukemia: clinical implications and opportunities for integrating genomics into clinical practice. Hematology. 2012; doi: 10.1179/102453312X13336169155411
17. The Cancer Genome Atlas Research Network. Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. N EnglJ Med. 2013;368:2059-2074. doi: 10.1056/NEJMoa1301689 PMID: 23634996
18. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. Version 2.2013 [Internet]. 1 Mar. 2013 [cited 5 Nov. 2014]. Available: http://www.nccn. org/professionals/physician-gls/PDF/aml.pdf
19. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-2333. PMID: 9746770
20. Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrozek K, Margeson D, et al. IDH1 and IDH2Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol. 2010;28:2348-2355. doi: 10.1200/JCO.2009.27.3730 PMID: 20368543
21. Gaidzik VI, Paschka P, Späth D, Habdank M, Köhne C-H, Germing U, et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol Off J Am SocClin Oncol. 2012;30:1350-1357. doi: 10.1200/JCO.2011.39.2886
22. Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V, et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia. 2013;27:82-91. doi: 10.1038/leu.2012.262 PMID: 23018865
23. Pratcorona M, Abbas S, Sanders MA, Koenders JE, Kavelaars FG, Erpelinck-Verschueren C A J, et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica. 2012;97:388-392. doi: 10.3324/haematol.2011.051532 PMID: 22058207
24. Tang J-L, Hou H-A, Chen C-Y, Liu C-Y, Chou W-C, Tseng M-H, et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood. 2009;114:5352-5361. doi: 10.1182/blood-2009-05-223784 PMID: 19808697
25. Damm F, Oberacker T, Thol F, Surdziel E, Wagner K, Chaturvedi A, et al. Prognostic Importance of Histone Methyltransferase MLL5 Expression in Acute Myeloid Leukemia. J Clin Oncol. 2011;29:682-689. doi: 10.1200/JCO.2010.31.1118 PMID: 21205756
26. Röllig C, Bornhäuser M, Kramer M, Thiede C, Ho AD, Krämer A, et al. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial. J Clin Oncol Off J Am SocClin Oncol. 2015;33:403-410. doi: 10.1200/JCO.2013.54.4973
27. Luskin MR, Lee J-W, Fernandez HF, Lazarus HM, Rowe JM, Tallman MS, et al. High Dose Daunorubicin Improves Survival in AML up to Age 60, Across All Cytogenetic Risk Groups Including Patients with Unfavorable Cytogenetic Risk, and FLT3-ITD Mutant AML: Updated Analyses from Eastern Cooperative Oncology Trial E1900. Oral Presentation 373. San Francisco, CA; 2014.
28. Dohner K. Prognostic Significance of Partial Tandem Duplications of the MLL Gene in Adult Patients 16 to 60 Years Old With Acute Myeloid Leukemia and Normal Cytogenetics: A Study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol. 2002;20:3254-3261. doi: 10.1200/JCO.2002.09.088 PMID: 12149299
29. Caligiuri MA, Strout MP, Lawrence D, Arthur DC, Baer MR, Yu F, et al. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res. 1998;58:55-59. PMID: 9426057